AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30693284 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Horseback Riding (THR)
Number of subjects: 0
Study 30693284 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30693439 — intervention group
Group type: EXPERIMENTAL
Intervention: RVX-208
Number of subjects: 2400
Study 30694208 — intervention group
Group type: EXPERIMENTAL
Intervention: Stay Strong + Coaching (intervention arm)
Number of subjects: 350
Study 30694208 — intervention group
Group type: COMPARATOR
Intervention: Stay Strong app (active comparator arm)
Number of subjects: 350
Study 30694612 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine biomarker with a minimal accepted sensitivity (MAS) of 90%
Number of subjects: 0
Study 30694612 — intervention group
Group type: COMPARATOR
Intervention: Cystoscopy
Number of subjects: 0
Study 30694612 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary biomarker
Number of subjects: 0
Study 30694829 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 0
Study 30695649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 0
Study 30696370 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficient iodine intake (188 μg/day [145-235 μg/day])
Number of subjects: 679
Study 30696422 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HIV self-testing kit
Number of subjects: 95
Study 30696422 — intervention group
Group type: COMPARATOR
Intervention: Blood-based HIV self-testing kit
Number of subjects: 95
Study 30696422 — intervention group
Group type: COMPARATOR
Intervention: Focus group discussions
Number of subjects: 95
Study 30696422 — intervention group
Group type: COMPARATOR
Intervention: HIVST kits
Number of subjects: 95
Study 30696435 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment
Number of subjects: 17096
Study 30696435 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies
Number of subjects: 17096
Study 30696475 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor/delta-ratio neurofeedback training
Number of subjects: 60
Study 30696475 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta1/theta-ratio neurofeedback training
Number of subjects: 60
Study 30696475 — intervention group
Group type: COMPARATOR
Intervention: Psycho-pedagogical care
Number of subjects: 60
Study 30696487 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 44
Study 30696669 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of asthma control during visits
Number of subjects: 884
Study 30696669 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalation of controller therapy during visits
Number of subjects: 884
Study 30696669 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery of asthma action plans
Number of subjects: 884
Study 30696950 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0
Study 30696950 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib + Ruxolitinib
Number of subjects: 0
Study 30696950 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (DEX)
Number of subjects: 0
Study 30697903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib (second-generation ALK inhibitor)
Number of subjects: 2
Study 30698147 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib
Number of subjects: 740
Study 30698534 — intervention group
Group type: EXPERIMENTAL
Intervention: T2T-based intervention programmes by speech and language therapists (SLTs)
Number of subjects: 7
Study 30698534 — intervention group
Group type: EXPERIMENTAL
Intervention: T2T software development and testing
Number of subjects: 7
Study 30698644 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus lenalidomide (R2); Rituximab 375/m2 i.v. on Day 1; Lenalidomide 20 mg/day (Day 1-21 for cycle 1), 25 mg/day (Day 1-21 for subsequent cycles); followed by maintenance of lenalidomide 10 mg/day for 12 cycles.
Number of subjects: 50
Study 30698656 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversation task (high social demand)
Number of subjects: 39
Study 30698656 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition task (low social demand)
Number of subjects: 39
Study 30698656 — intervention group
Group type: COMPARATOR
Intervention: Resting state data
Number of subjects: 39
Study 30698656 — intervention group
Group type: EXPERIMENTAL
Intervention: Task and rest context
Number of subjects: 39
Study 30698656 — intervention group
Group type: EXPERIMENTAL
Intervention: Striato- and thalamocortical relationships
Number of subjects: 39
Study 30699849 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroticism
Number of subjects: 296
Study 30699849 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive control
Number of subjects: 296
Study 30699849 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward learning
Number of subjects: 296
Study 30699881 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone (15-45 mg/day)
Number of subjects: 38
Study 30699881 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 38
Study 30699881 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 38
Study 30700274 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination (at least one dose)
Number of subjects: 767
Study 30700274 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonavalent vaccine
Number of subjects: 767
Study 30700274 — intervention group
Group type: COMPARATOR
Intervention: Quadrivalent vaccine
Number of subjects: 767
Study 30700274 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV genotype distribution
Number of subjects: 767
Study 30700274 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and behavioral factors comparison
Number of subjects: 767
Study 30700568 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 150 mg tablet twice daily combined with metronomic carboplatin AUC2 and paclitaxel 60 mg/m2
Number of subjects: 54
Study 30700614 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge chemotherapy
Number of subjects: 124
Study 30700614 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge radiation
Number of subjects: 124
Study 30700614 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe acute pain
Number of subjects: 124
Study 30700614 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate acute pain
Number of subjects: 124
Study 30700614 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased duration of surgery, higher pain catastrophizing score, and surgeon
Number of subjects: 124
Study 30700614 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation
Number of subjects: 124
Study 30700614 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent pain
Number of subjects: 124
Study 30700726 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh mother's own milk once daily from enrollment until 32 weeks' corrected age
Number of subjects: 207
Study 30701079 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV DNA PCR testing at birth
Number of subjects: 4
Study 30701079 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert HIV-1 Qual
Number of subjects: 4
Study 30701079 — intervention group
Group type: EXPERIMENTAL
Intervention: Alere q HIV-1/2 Detect
Number of subjects: 4
Study 30701079 — intervention group
Group type: COMPARATOR
Intervention: Standard HIV DNA PCR testing at 6 weeks
Number of subjects: 4
Study 30701294 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored multicomponent program for discomfort reduction
Number of subjects: 1537
Study 30701294 — intervention group
Group type: COMPARATOR
Intervention: Unexposed patients
Number of subjects: 1537
Study 30701920 — intervention group
Group type: EXPERIMENTAL
Intervention: ALL-2009 protocol
Number of subjects: 115
Study 30701920 — intervention group
Group type: EXPERIMENTAL
Intervention: FISH technique
Number of subjects: 115
Study 30701920 — intervention group
Group type: EXPERIMENTAL
Intervention: MLL/t(11q23) and c-MYC/t(8q24) gene abnormalities
Number of subjects: 115
Study 30701920 — intervention group
Group type: EXPERIMENTAL
Intervention: CDKN2A/9p21 and TP53/17p13 gene deletions, quantitative and complex karyotype abnormalities
Number of subjects: 115
Study 30702005 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30702430 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive
Number of subjects: 274
Study 30702430 — intervention group
Group type: EXPERIMENTAL
Intervention: Charity incentive
Number of subjects: 274
Study 30702430 — intervention group
Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 274
Study 30702430 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring prompts
Number of subjects: 274
Study 30702430 — intervention group
Group type: COMPARATOR
Intervention: No self-monitoring prompts
Number of subjects: 274
Study 30702430 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning interventions
Number of subjects: 274
Study 30702430 — intervention group
Group type: COMPARATOR
Intervention: No planning interventions
Number of subjects: 274
Study 30703536 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-reported uncontrolled asthma
Number of subjects: 2
Study 30703536 — intervention group
Group type: COMPARATOR
Intervention: Caregiver-reported well-controlled asthma
Number of subjects: 2
Study 30703787 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy after high-quality cytoreductive surgery (CRS)
Number of subjects: 0
Study 30703787 — intervention group
Group type: COMPARATOR
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin
Number of subjects: 0
Study 30703787 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen (oxaliplatin and fluorouracil)
Number of subjects: 0
Study 30703787 — intervention group
Group type: EXPERIMENTAL
Intervention: Total neoadjuvant therapy (TNT)
Number of subjects: 0
Study 30703787 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0
Study 30703787 — intervention group
Group type: EXPERIMENTAL
Intervention: Checkmate-142 study for advanced tumors
Number of subjects: 0
Study 30703787 — intervention group
Group type: EXPERIMENTAL
Intervention: NCT03026140 study on neoadjuvant treatment for early tumors
Number of subjects: 0
Study 30703787 — intervention group
Group type: EXPERIMENTAL
Intervention: New targeted drugs (Eltanexor and cobimetinib)
Number of subjects: 0
Study 30704282 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized multiphasic coronary CT angiography
Number of subjects: 50
Study 30704447 — intervention group
Group type: EXPERIMENTAL
Intervention: Push mechanisms (e.g. poor health, poor working environment, age discrimination)
Number of subjects: 15721
Study 30704447 — intervention group
Group type: EXPERIMENTAL
Intervention: Stay mechanisms (e.g. attractive working conditions, good working environment)
Number of subjects: 15721
Study 30704447 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire covering 14 domains related to labour market participation
Number of subjects: 15721
Study 30704483 — intervention group
Group type: EXPERIMENTAL
Intervention: AMAP (Altered Muscle Activation Patterns)
Number of subjects: 54
Study 30704483 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 54
Study 30704832 — intervention group
Group type: EXPERIMENTAL
Intervention: Single cycle length method for calculating EOA in AF patients
Number of subjects: 100
Study 30704832 — intervention group
Group type: EXPERIMENTAL
Intervention: Single cycle length method on a postextrasystolic beat
Number of subjects: 100
Study 30704882 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV seropositive patients
Number of subjects: 442171
Study 30704882 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-seropositive donor kidney
Number of subjects: 442171
Study 30704966 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-Pugh (CP) score
Number of subjects: 230
Study 30704966 — intervention group
Group type: EXPERIMENTAL
Intervention: ALBI score
Number of subjects: 230
Study 30704966 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic model including CP or MELD
Number of subjects: 230
Study 30705758 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiprodil oral suspension (30 mg, 12 mL)
Number of subjects: 10
Study 30705758 — intervention group
Group type: COMPARATOR
Intervention: Conventional venous sampling
Number of subjects: 10
Study 30705758 — intervention group
Group type: COMPARATOR
Intervention: Mitra™ microsampling
Number of subjects: 10
Study 30705758 — intervention group
Group type: COMPARATOR
Intervention: Aqua-Cap™ Drummond microsampling
Number of subjects: 10
Study 30706154 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder type II
Number of subjects: 84
Study 30706431 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF) with GI management strategies
Number of subjects: 809
Study 30706431 — intervention group
Group type: COMPARATOR
Intervention: Counseling about GI events and recommendations for DMF administration
Number of subjects: 809
Study 30706431 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic therapies for GI AEs
Number of subjects: 809
Study 30706490 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly prednisolone (5 mg/kg/dose)
Number of subjects: 25
Study 30706490 — intervention group
Group type: COMPARATOR
Intervention: Historical control cohort (HCC) - untreated boys
Number of subjects: 25
Study 30706561 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents with psychosis
Number of subjects: 545
Study 30706561 — intervention group
Group type: COMPARATOR
Intervention: Residents with psychosis without antipsychotic medication
Number of subjects: 545
Study 30706646 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric electrical stimulation (GES) for 5-7 days, followed by permanent GES for 30 patients at 6 months follow-up.
Number of subjects: 43
Study 30706753 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation interventions for smokers with chronic pain
Number of subjects: 1093
Study 30707098 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Wii Fit balance board
Number of subjects: 58
Study 30707510 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional relative weight gain
Number of subjects: 316
Study 30707510 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 to 2 years of age
Number of subjects: 316
Study 30708069 — intervention group
Group type: EXPERIMENTAL
Intervention: Clown distraction
Number of subjects: 59
Study 30708069 — intervention group
Group type: COMPARATOR
Intervention: Control distraction
Number of subjects: 59
Study 30708264 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 (3.6 mg/kg every 3 weeks)
Number of subjects: 2002
Study 30709364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal delivery of a viral vector in a Phase I gene therapy clinical trial for GAN.
Number of subjects: 0
Study 30709417 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist consultations
Number of subjects: 585
Study 30709417 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist recommendations
Number of subjects: 585
Study 30709417 — intervention group
Group type: EXPERIMENTAL
Intervention: Alerts regarding potentially inappropriate DOAC doses
Number of subjects: 585
Study 30709417 — intervention group
Group type: EXPERIMENTAL
Intervention: Alerts regarding potentially inappropriate concomitant antiplatelet agents
Number of subjects: 585
Study 30709417 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for DOAC level monitoring
Number of subjects: 585
Study 30709417 — intervention group
Group type: EXPERIMENTAL
Intervention: Alerts regarding other drug related problems
Number of subjects: 585
Study 30709431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ublituximab (900 mg IV), Umbralisib (800 mg orally once daily), Ibrutinib (420 mg for CLL, 560 mg for NHL)
Number of subjects: 46
Study 30709431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ublituximab, Umbralisib, and Ibrutinib combination
Number of subjects: 46
Study 30710527 — intervention group
Group type: EXPERIMENTAL
Intervention: Treg cells incubated with rapamycin and RARA agonist (RAR568)
Number of subjects: 0
Study 30710527 — intervention group
Group type: COMPARATOR
Intervention: Treg cells incubated with rapamycin alone or rapamycin with all-trans retinoic acid
Number of subjects: 0
Study 30710573 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucaloric diet (EBL, 50% carbohydrate, n=37)
Number of subjects: 53
Study 30710573 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (FNP, 60% fat, n=25)
Number of subjects: 53
Study 30710573 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (CNP, 75% carbohydrate, n=24)
Number of subjects: 53
Study 30710613 — intervention group
Group type: EXPERIMENTAL
Intervention: History of bullying before the age of 18
Number of subjects: 186
Study 30710613 — intervention group
Group type: COMPARATOR
Intervention: No self-reported history of bullying
Number of subjects: 186
Study 30710687 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine/methotrexate
Number of subjects: 200
Study 30710687 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus/sirolimus
Number of subjects: 200
Study 30711626 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon mucosal impedance (MI) catheter system
Number of subjects: 69
Study 30711772 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 1238097 at 10 mg/week
Number of subjects: 8
Study 30711772 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 1238097 at 40 mg/week
Number of subjects: 8
Study 30711772 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 1238097 at 80 mg/week
Number of subjects: 8
Study 30711772 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 1238097 (all doses)
Number of subjects: 8
Study 30711970 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) plus interferon alpha-2a (IFN)
Number of subjects: 359
Study 30712097 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week individualized yoga intervention (in-person and remote via Skype)
Number of subjects: 10
Study 30712097 — intervention group
Group type: EXPERIMENTAL
Intervention: Homework assigned between sessions
Number of subjects: 10
Study 30713028 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma vitamin E levels
Number of subjects: 229
Study 30713028 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma vitamin E levels with high selenium levels (median≥83.7 μg/L)
Number of subjects: 229
Study 30713028 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma vitamin E levels with low selenium levels (<83.7 μg/L)
Number of subjects: 229
Study 30713498 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (initially at a low dose of 150 mg/m2)
Number of subjects: 1
Study 30713498 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoids
Number of subjects: 1
Study 30713498 — intervention group
Group type: COMPARATOR
Intervention: Immunoglobulin dose escalation
Number of subjects: 1
Study 30713538 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimpanzee adenoviral vectors vaccine
Number of subjects: 0
Study 30713786 — intervention group
Group type: EXPERIMENTAL
Intervention: ONCOS-102
Number of subjects: 0
Study 30713786 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ONCOS-102 and pembrolizumab
Number of subjects: 0
Study 30713786 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab (200 µg or 400 µg)
Number of subjects: 0
Study 30713786 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight loss and metastasis
Number of subjects: 0
Study 30713992 — intervention group
Group type: EXPERIMENTAL
Intervention: Supernumerary sex chromosomes
Number of subjects: 0
Study 30714026 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led, technology-aided intervention
Number of subjects: 60
Study 30714080 — intervention group
Group type: EXPERIMENTAL
Intervention: Group brainstorming session A
Number of subjects: 52
Study 30714080 — intervention group
Group type: EXPERIMENTAL
Intervention: Group brainstorming session B
Number of subjects: 52
Study 30714080 — intervention group
Group type: EXPERIMENTAL
Intervention: Group brainstorming session C
Number of subjects: 52
Study 30714080 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of two sessions (A+B, A+C, B+C)
Number of subjects: 52
Study 30714174 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV-hG6PC-S298C vector
Number of subjects: 0
Study 30714174 — intervention group
Group type: COMPARATOR
Intervention: rAAV-hG6PC-WT vector
Number of subjects: 0
Study 30714174 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV-co-hG6PC vector
Number of subjects: 0
Study 30714202 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) plus clinical management
Number of subjects: 80
Study 30714202 — intervention group
Group type: COMPARATOR
Intervention: Clinical management only
Number of subjects: 80
Study 30714570 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenestrated-branched endovascular aneurysm repair (F-BEVAR)
Number of subjects: 159
Study 30714833 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30714987 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoantigen screening for TP53 mutations
Number of subjects: 0
Study 30715229 — intervention group
Group type: EXPERIMENTAL
Intervention: Active HCV
Number of subjects: 327
Study 30715229 — intervention group
Group type: COMPARATOR
Intervention: Sustained virologic response (SVR)
Number of subjects: 327
Study 30715229 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-SVR
Number of subjects: 327
Study 30715232 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical Thickness (CT)
Number of subjects: 813
Study 30715232 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal association cortex and language centers
Number of subjects: 813
Study 30715232 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared genetic factors
Number of subjects: 813
Study 30715588 — intervention group
Group type: EXPERIMENTAL
Intervention: Body composition markers
Number of subjects: 1121
Study 30715588 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal muscle mass index (SMI)
Number of subjects: 1121
Study 30715944 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockwave Coronary Intravascular Lithotripsy
Number of subjects: 0
Study 30715944 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30716132 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extension force
Number of subjects: 48